Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain JNJ message board posts where the ticker symbol JNJ has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest JNJ SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-17-018692 Size: 4 KB
2017-12-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-17-018691 Size: 5 KB
2017-12-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-17-018690 Size: 7 KB
2017-12-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000904454-17-000692 (34 Act)  Size: 6 KB
2017-11-22 001-33095
171218973
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000904454-17-000690 Size: 35 KB
2017-11-22
8-K  Documents Current report, items 1.01, 8.01, and 9.01
Acc-no: 0001193125-17-339898 (34 Act)  Size: 61 KB
2017-11-13 001-03215
171193216
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-17-338979 (33 Act)  Size: 453 KB
2017-11-09 333-216285
171191817
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001193125-17-338831 (34 Act)  Size: 95 KB
2017-11-09 001-03215
171191294
FWP  Documents Filing under Securities Act Rules 163/433 of free writing prospectuses
Acc-no: 0001193125-17-337532 (34 Act)  Size: 27 KB
2017-11-09 333-216285
171187848
424B3  Documents Prospectus [Rule 424(b)(3)]
Acc-no: 0001193125-17-336499 (33 Act)  Size: 441 KB
2017-11-08 333-216285
171185119
More JNJ SEC Filings


Related news from
Sat, 16 Dec 2017
15:33:00 +0000
Better Buy: Johnson & Johnson vs. Merck
J&J stock is up in 2017, while Merck is down. But could the roles be reversed in 2018 and beyond?
Sat, 16 Dec 2017
01:21:00 +0000
3 Dividend Stocks With Better Yields Than Johnson & Johnson
These stocks would serve your income portfolio better than Johnson & Johnson today.
Fri, 15 Dec 2017
19:37:07 +0000
Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
Fri, 15 Dec 2017
14:21:02 +0000
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
Fri, 15 Dec 2017
11:04:00 +0000
What to Expect From AbbVie Inc. in 2018
The short answer: More good things.
Thu, 14 Dec 2017
21:03:09 +0000
Top Analyst Reports for Microsoft, Johnson & Johnson & ExxonMobil
Top Analyst Reports for Microsoft, Johnson & Johnson & ExxonMobil
Thu, 14 Dec 2017
20:34:08 +0000
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Thu, 14 Dec 2017
18:17:36 +0000
US STOCKS-S&P, Dow flat as healthcare losses offset by tech, media gains
The S&P 500 and the Dow were trading flat in early afternoon on Thursday as losses in healthcare stocks such as Johnson & Johnson were offset by gains in shares of technology and consumer discretionary companies. Walt Disney struck a deal to buy Twenty-First Century Fox's assets for $52.4 billion in stock.
Thu, 14 Dec 2017
17:38:19 +0000
Valeant Pharmaceuticals’ Siliq Approved for Plaque Psoriasis
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
Thu, 14 Dec 2017
17:38:11 +0000
Johnson & Johnson’s Tremfya Approved to Treat Plaque Psoriasis
In July 2017, the US FDA (Food and Drug Administration) approved Johnson & Johnson’s (JNJ) Tremfya (guselkumab) for the treatment of individuals with moderate to severe plaque psoriasis.
Thu, 14 Dec 2017
16:04:42 +0000
Carnival of Berkshire #2
Collection of links to articles that offer value
Thu, 14 Dec 2017
15:28:07 +0000
Bristol-Myers Squibb’s Valuation in December 2017
Headquartered in New York City, pharmaceutical giant Bristol-Myers Squibb (BMY) offers various cardiovascular, immunoscience, neuroscience, oncology, and virology products.
Thu, 14 Dec 2017
03:55:47 +0000
2018 Outlook for Asia's Airline Industry
Dec.13 -- Corrine Png, founder and chief executive officer at Crucial Perspective, discusses her outlook for Asia's airline industry in 2018. She speaks on "Bloomberg Markets: Asia."
Thu, 14 Dec 2017
01:09:58 +0000
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer's Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn's disease and skin disorder plaque psoriasis, the drugmaker said. With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc's Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea's Samsung Bioepis Co Ltd.
Wed, 13 Dec 2017
15:10:20 +0000
A Trendy New ETF From Pacer
Pacer, the exchange traded funds issuer behind a unique suite of trend-following funds, added to its lineup Tuesday with the debut of the Pacer WealthShield ETF (CBOE: PWS). The new ETF tracks the Pacer ...
Wed, 13 Dec 2017
13:00:00 +0000
Here's Why Everyone's So Excited About bluebird bio
A next-generation cancer treatment could significantly change multiple myeloma outcomes for thousands of people, generating hundreds of millions of dollars in sales for the company.
Wed, 13 Dec 2017
12:31:00 +0000
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Wed, 13 Dec 2017
08:00:00 +0000
Abbott Laboratories Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Abbott Laboratories shows improving technical performance.
Tue, 12 Dec 2017
22:49:10 +0000
Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
Tue, 12 Dec 2017
21:12:08 +0000
Markets Right Now: Banks lead US stock indexes mostly higher
The latest on developments in financial markets (All times local): 4 p.m. Big-company stocks notched gains on Wall Street, bringing more records for major indexes, but smaller companies lagged behind. ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards